Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20914077 | 0.89 | TNKS (0.37) | MEN1CYP1A2CYP2C9PKMTSHR | |
| SCHEMBL20913968 | 0.84 | KDM4E (0.34) | MEN1CYP1A2CYP2C9PKMTSHR | |
| SCHEMBL20837038 | 0.84 | ADORA2A (0.34) | MEN1CYP1A2CYP2C9PKMTSHR | |
| SCHEMBL20913931 | 0.83 | KMT2A (0.35) | MEN1CYP1A2CYP2C9PKMTSHR | |
| SCHEMBL20914080 | 0.83 | KMT2A (0.32) | MEN1CYP1A2CYP2C9PKMTSHR | |
| SCHEMBL20914299 | 0.83 | CYP1A2 (0.35) | MEN1CYP1A2CYP2C9PKMTSHR | |
| SCHEMBL20837241 | 0.82 | PLAT (0.35) | HTR3AMEN1KMT2A | |
| SCHEMBL20837037 | 0.81 | P2RY6 (0.37) | MEN1CYP1A2CYP2C9PKMTSHR | |
| SCHEMBL20837249 | 0.81 | TNKS (0.37) | MEN1CYP1A2CYP2C9KMT2A | |
| SCHEMBL20913913 | 0.81 | KCNA5 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | HTR3A 2505/4885MEN1 2785/4885CYP1A2 1015/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | HTR3A 2505/4885MEN1 2785/4885CYP1A2 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.